Regener-Eyes offering $10,000 academic scholarship

February 18, 2021
David Hutton

Applicants must submit an original essay focusing on how biologics are transforming regenerative medicine in eye care. The deadline to apply is March 12.

The application deadline is approaching for a $10,000 scholarship launched by Regenerative Processing Plant, LLC, the maker the biologic eye drop Regener-Eyes.

The company will offer a new scholarship to a post-secondary student in 2021. The application deadline is March 12, 2021, and applications can be submitted online at: https://regener-eyesscholarship.com/apply-now.

To be eligible for the scholarship, applicants must have an acceptance letter to an accredited college or university in the U.S. or Canada. A copy of the letter must be included with the application.

Applicants also are required to submit a 400-word original essay detailing how biologics are transforming regenerative medicine in eye care. They are also asked to provide a photo of themselves, which will be included in a press release if they are ultimately awarded the scholarship.

C. Randall Harrell, MD, CEO and founder of Regener-Eyes, pointed out that there is great potential for biologics to transform regenerative medicine in eye care.

“We look forward to helping a promising and ambitious student significantly defray the costs of their education, so they can achieve their potential and make a meaningful contribution on whichever career path they choose to pursue,” he said in a statement.

Regener-Eyes is a sterile biologic eye drop made of anti-inflammatory cytokines and growth factors. These kinds of proteins are necessary for cell function, overall health, and homeostasis and have been shown to reduce inflammation, and help stimulate the ocular surface to heal, repair, and regenerate. The professionals at Regener-Eyes claim that the product may be a solution for patients who are unresponsive to their current eye drugs or are amniotic membrane intolerant.

Dry eye specialists, including Marguerite McDonald, MD, FACS and Paul Karpecki, OD, FAAO have seen positive results among their Regener-Eyes patients.

Regener-Eyes is available in LITE (suitable for mild to moderate patients) and professional strength (for more severe patients). Both formulations have a three-year shelf life and can be self-administered by patien

ts on a daily basis. Currently, there are no known contraindications.

“The science of regenerative medicine focuses on stimulating the body’s own natural ability to heal and

regenerate,” Harrell said in the statement. “Regener-Eyes may offer hope to many patients.”